ACC Decision Pathway Provides New Guidance on Managing T2D Patients With ASCVD
The ACC's new 2018 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease addresses the changing paradigm in how cardiovascular specialists should approach care of type 2 diabetes (T2D) patients.
The Pathway, which is endorsed by the American Diabetes Association and published in the Journal of the American College of Cardiology, identifies three key areas where cardiovascular professionals are uniquely positioned to assist with the management of T2D patients: 1) screening for T2D in patients with or at high risk of cardiovascular disease; 2) aggressively treating cardiovascular risk factors; and 3) incorporating data for newer antihyperglycemic agents into routine practice.
Of note, the Pathway provides practical guidance on when and how to incorporate the use of SGLT2 inhibitors and GLP-1Ras in the treatment of patients with T2D and ASCVD with the express goal of reducing cardiovascular risk and optimizing outcomes. Read more.